Orionis has developed two transformative technology platforms. While technologically distinct, addressing small and large molecules, they both harness proximity and cooperativity mechanisms in drug mode of action. These innovations are leveraged to create precision medicines that engage with, modulate or dispose of disease targets with a high degree of selectivity, limiting off-target interactions and minimizing potential for drug liabilities.